Actelion CFO suddenly replaced with Pierre Fabre exec; Galderma wins FDA nod for rosacea treatment Mirvaso;

@FiercePharma: Sudden CFO departure at Actelion, just as Swiss drug maker wraps up Ceptaris buyout. More | Follow @FiercePharma

@EricPFierce: Swiss CMO Siefried building a manufacturing plant in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Low vaccination rate at megachurch linked to measles outbreak. Story | Follow @CarlyHFierce

> The Swiss drugmaker Actelion ($ATLN) says CFO Andrew Oakley will leave the company next week, to be replaced by Pierre Fabre's current CFO, Andre Muller. Report

> Galderma won FDA approval for its Mirvaso topical gel to treat facial redness in patients with rosacea. Report

> Beef supplier Cargill says it will stop accepting cattle fed with Merck's ($MRK) Zilmax by the end of September, after the drugmaker suspended sales and started investigating safety concerns. Report

> The U.K.'s Cancer Drugs Fund, which helps pay for expensive treatments not approved by cost-effectiveness gatekeepers, will assist more than 16,500 patients this fiscal year, a cancer charity said. Report

> Novo Nordisk ($NVO) launched a $3 million diabetes prevention program in South Dakota, aimed at reducing the incidence of the disease on the Rosebud Sioux Tribe reservation. Report

> Hyderabad, India-based vaccines maker Bharat Biotech launched a typhoid conjugate shot, Typbar-TCV, for children and adults in the domestic market. Report

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter tomorrow. Sign up here | Follow @FierceMedDev

@DamianFierce: Covidien has opened the doors of a new $21M South Korean R&D shop. More | Follow @DamianFierce

@MarkHFierce: Edwards, fresh from a patent lawsuit victory, is heralding a German injunction on Medtronic CoreValve sales. Story | Follow @MarkHFierce

@MichaelGFierce: Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien cuts ribbon on $21M Korean R&D shop. Report

> New sleep apnea treatment devices emerge. Story

> LDR files for $69M IPO following FDA approval. Article

> Volcano buying Medtronic's imaging catheter. News

> Vestagen pulls in $8.25 million for high-tech medical scrub uniforms. Item

Biotech News

@FierceBiotech: Syndax snags $26.6M round for Phase III breast cancer study. More | Follow @FierceBiotech

@JohnCFierce: Patient advocacy or Amgen's blockbuster protection act? Biosimilars bills advance. Report | Follow @JohnCFierce

> Acura investors feel the pain as abuse-deterrence tech flops in PhII. More

> Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA. News

Biotech Research News

@EmilyMFierce: Omega-3 alleviates ADHD symptoms in rats. More | Follow @EmilyMFierce

> High copper levels implicated in Alzheimer's disease. Story

> Single injection could provide new treatment for melanoma. Article

> New target to battle Parkinson's discovered. News

> Gene therapy in mice improves Rett syndrome. More

> Sodium 'switch' could provide target to treat brain disorders. Item

Pharma Manufacturing News

> Akorn buys Hi-Tech for $640M to tap manufacturing expertise. Report

> Amarin asks FDA to approve Novasep as Vascepa partner. Story

> Lonza starting job cuts at troubled U.S. biologics plant. Article

> Ontario helps Pillar5 expand plant. Item

> Another Fresenius plant in FDA crosshairs. More

And Finally... How about a marriage drug? Scientists posit that intranasal oxytocin could strengthen long-term relationships. More

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.